You are here

The global uveitis drugs market size at a CAGR of around 7% during 2019-2023

NEW YORK, June 17, 2019 /PRNewswire/ -- About this market

Several risk factors associated with uveitis had been a challenge during the diagnosis of eye disorders. Considering the complexities related to the diagnosis, vendors in the market are developing novel diagnostic tools and methods to treat patients with uveitis. Several companies are introducing AI-implemented medical devices to detect the level of diabetic retinopathy in patients with diabetes. Devices integrated with AI work autonomously and eliminate the need for specialists to make clinical decisions. Many such advancements have made the diagnosis of eye conditions easier. Ophthalmologists are leveraging such technical advantages and are providing the right treatment to patients. This is expected to drive the growth of the global uveitis drugs market size at a CAGR of around 7% during 2019-2023.

Read the full report:

Market Overview

High prevalence of eye disorders and associated risk factors of uveitis

Uveitis is associated with several inflammatory diseases that cause swelling and destroy eye tissues. People with AIDS, rheumatic arthritis, multiple sclerosis, TB, and syphilis are more vulnerable to eye-related risk factors. The high prevalence of these diseases will have a positive impact on the market's growth.

Availability of substitutes

Despite the availability of approved drugs, healthcare practitioners are adopting alternative treatment options such as surgery, laser treatment, and biopsy due to the side-effects associated with uveitis drugs. This is expected to hinder the growth of the global uveitis drugs market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the uveitis drugs market size during 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented with several players occupying the market share. Companies such as AbbVie Inc. and Allergan Plc have intensified competition. Factors such as the recent advancements in the diagnosis of eye disorders and the high prevalence of eye disorders and associated risk factors of uveitis will provide significant growth opportunities for uveitis drug companies. AbbVie Inc., Allergan Plc, Johnson & Johnson Services Inc., Novartis AG, and Pfizer Inc. are some of the major companies covered in this report.

Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Contact Clare:
US: (339)-368-6001
Intl: +1 339-368-6001

Cision View original content:

SOURCE Reportlinker